LZM-004

重组全人源抗RANKL单克隆抗体（丽珠单抗生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLZM-004
Drug Alias Name重组全人源抗RANKL单克隆抗体注射液（丽珠单抗生物）LZM-004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLivzon(Group) Pharmaceutical Factory
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLivzon Mabpharm Inc
Inactive CompaniesN/A
Active IndicationsBone metastases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A